Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01189 (
beta-endorphin
)
21,003
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Morphine
(30--80 nA) and
met-enkephalin
(30--80 nA) decreased the excitability of single sural Adelta afferent terminals and potentiated the enhancement of the terminal excitability produced by superficial peroneal nerve stimulation, in mid-collicular decerebrate and spinalized cats. Naloxone (20--40 nA) antagonized the actions of both substances on the unconditioned and the conditioned terminal excitabilities. These results indicate that morphine and
met-enkephalin
hyperpolarize Adelta sural afferent terminals and facilitate the terminal depolarization during presynaptic inhibition. This enhancement of presynaptic inhibition may be, at least partly, responsible for the analgesic action of these agents.
...
PMID:Morphine and met-enkephalin effects on sural Adelta afferent terminal excitability. 68 79
The mapping of the forebrain regions sensitive to
beta-endorphin
and morphine for antinociception was performed in pentobarbital-anesthetized rats. The antinociception was assessed by the tail-flick test. The sites most sensitive to
beta-endorphin
(2 micrograms) for inhibition of the tail-flick response were located in the ventromedial regions of the forebrain such as medial posterior nucleus accumbens, medial preoptic area and arcuate hypothalamic nucleus. Other areas such as anterior nucleus accumbens, dorsomedial hypothalamic nucleus, posterior hypothalamus, lateral hypothalamus, caudate nuclei, thalami and cerebral cortex were not sensitive to
beta-endorphin
for the tail-flick inhibition. The sites sensitive to morphine sulfate (4 micrograms) for inhibition of the tail-flick response were located in regions of medial preoptic nucleus and arcuate hypothalamic nucleus. Posterior nucleus accumbens, which is sensitive to
beta-endorphin
, was not sensitive to morphine for antinociception.
Morphine
injected into this site did not produce tail-flick inhibition in both conscious and pentobarbital-anesthetized rats. The inhibition of the tail-flick response induced by
beta-endorphin
(2 micrograms) from posterior nucleus accumbens, medial preoptic area and arcuate hypothalamic nucleus was blocked by the administration of
beta-endorphin
-(1-27), an epsilon opioid receptor blocker, but not by D-Phe-Cys-Tyr-D-Try-Orn-Thr-Pen-Thr-NH2, a mu opioid receptor blocker. On the other hand, the inhibition induced by morphine (4 micrograms) from medial preoptic area and arcuate hypothalamic nucleus was blocked by D-Phe-Cys-Tyr-D-Try-Orn-Thr-Pen-Thr-NH2, but not by
beta-endorphin
-(1-27).(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Forebrain sites differentially sensitive to beta-endorphin and morphine for analgesia and release of Met-enkephalin in the pentobarbital-anesthesized rat. 131 68
Etorphine, a potent opioid agonist, has been reported to bind to both mu and epsilon opioid receptors. The present studies were designed to determine what types of opioid receptors and neurotransmitters for descending pain control systems were involved in antinociception induced by etorphine in mice.
Morphine
, a typical mu opioid receptor agonist, and
beta-endorphin
, an epsilon opioid receptor agonist, were used for comparison. Antinociceptive response induced by etorphine (20 ng) given i.c.v was blocked by i.c.v administration of D-Phe-Cys-Tyr-D-Tyr-Orn-Thr-Pen-Thr-NH2 (CTOP, 25 ng) and
beta-endorphin
-(1-27) [beta-EP-(1-27)] (6 micrograms), but not ICI 174,864 (ICI, 5 micrograms) or norbinaltorphimine (N-BNI, 5 micrograms). The antinociception induced by i.c.v. etorphine was also antagonized by the i.c.v. pretreatment of beta-funaltrexamine (beta-FNA, 50 ng, 24 hr). Intracerebroventricular administration of beta-EP-(1-27) (3 micrograms) caused a further attenuation of the i.c.v. etorphine-induced antinociception in mice pretreated with beta-FNA. The antinociceptive response induced by morphine (2 micrograms) given i.c.v. was blocked by i.c.v. administration of CTOP (25 ng) or beta-FNA (50 ng), but not beta-EP-(1-27) (6 micrograms), ICI (5 micrograms) or N-BNI (5 micrograms). These results indicate that the antinociception induced by etorphine given i.c.v. is mediated by the stimulation of both mu and epsilon opioid receptors whereas the antinociception induced by morphine given i.c.v. is mediated by the stimulation of mu, but not epsilon opioid receptors at supraspinal sites.(ABSTRACT TRUNCATED AT 250 WORDS)
...
PMID:Involvement of supraspinal epsilon and mu opioid receptors in inhibition of the tail-flick response induced by etorphine in the mouse. 132 9
The effect of endogenous opioid peptides (EOP) on LH secretion is variable during different physiological states. A series of experiments concerning the role of EOP on LH secretion in cyclic gilts was performed. They were comprised of (1) an administration of an opioid antagonist or agonist in gilts during the estrous cycle and in ovariectomized (OVX) gilts in which the LH surge was induced with estradiol benzoate (EB) and (2) in vitro studies on GnRH release from the stalk median eminence (SME) of cyclic gilts and OVX estrogen and progesterone primed gilts in response to naloxone (NAL). Naloxone and
met-enkephalin
analogue (FK 33-824) administration as a single independent injections did not affect LH secretion during the early (Day 16) or late (Day 19 or 20) follicular phase. However, continuous infusion of FK 33-824 for 4 h decreased LH secretion during the infusion period on Day 19 of the estrous cycle.
Morphine
also exerts an inhibitory effect on the EB-induced LH surge during the positive feedback phase (60-64 h after EB administration) in OVX gilts. On the contrary, NAL infusion in OVX gilts during the negative feedback phase (30-34 h after EB administration) did not alter LH secretion. A single injection of FK 33-824 in luteal phase gilts decreased the number of LH pulses for a 3 h period. This allows to hypothesize that EOP participates in the regulation of pulsatile LH secretion in pigs during the luteal phase. In vitro studies indicate that influence of EOP on LH secretion also takes place at the SME level. GnRH efflux from the SME of gilts during the luteal and late follicular phases was augmented in the presence of NAL. Unexpectedly, the priming of OVX gilts with estrogens caused the highest increase in GnRH release from the SME in vitro in response to NAL. These results confirm the variety of functional links between the opioid system and LH secretion in gilts during different stages of the estrous cycle.
...
PMID:Influence of opioids on LH secretion in gilts during the estrous cycle. 134 63
Thirty cancer patients, clinical group IV, have been examined. It has been established that a persistent pain syndrome leads to lowering in
beta-endorphin
liquor level.
Morphine
analgesia is followed by
beta-endorphin
level elevation which directly depends on pain intensity and analgesia efficacy. Determination of changes in
beta-endorphin
liquor level may serve as a criterion of analgesia efficacy.
...
PMID:[Changes in the concentration of beta-endorphin in the cerebrospinal fluid due to morphine analgesia in incurable oncologic patients]. 141 98
Interactions between opiates and the human immune system have important clinical implications. To further evaluate these interactions, we studied in vitro and in vivo effects of morphine sulfate (morphine) and
beta-endorphin
(Bend) on antibody-dependent cell cytotoxicity (ADCC), natural killer cell cytotoxicity (NKCC), and effector cell expression of antibody Fc receptors.
Morphine
and Bend had no potent in vivo or in vitro effect on FcR expression nor did they have a significant in vitro effect on ADCC by monocytes or polymorphonuclear cells. Bend enhancement of NKCC in vitro was inhibited by coincubation of effector cells with morphine. After taking 90 to 150 mg of oral morphine, study volunteers demonstrated a significant decrease in ADCC by peripheral blood mononuclear cells. The same individuals demonstrated a consistent increase in NKCC and no change in the expression of Fc receptors. Effector cells from these individuals responded normally to in vitro incubation with interferon-gamma (IFN-gamma).
...
PMID:Effect of morphine and beta-endorphin on human Fc receptor-dependent and natural killer cell functions. 154 Oct 57
It has been proposed that a serial, unidirectional circuit from the PAG to the N. accumbens and the amygdala are involved in antinociception and that enkephalins (ENK) and
beta-endorphin
(beta-EP) act as neurotransmitters in this circuitry. In the present study, we measured the release of ENK and beta-EP by simultaneous push-pull perfusion of the N. accumbens and amygdala after microinjection of morphine into the PAG.
Morphine
administration elicited an increase in immunoreactive ENK and beta-EP in both the N. accumbens and the amygdala, which was antagonized in each nucleus by perfusion with naloxone. These data suggest that the three nuclei were not serially connected and that they may take part in one and the same antinociceptive system with an "all or none" character.
...
PMID:Naloxone blocks opioid peptide release in N. accumbens and amygdala elicited by morphine injected into periaqueductal gray. 159 57
The antinociceptive effects of morphine and
beta-endorphin
given intracerebroventricularly (i.c.v.) or intrathecally (i.t.) were evaluated by inhibition of the tail-flick and hot-plate paw-licking responses evoked by three different intensities of heat stimulation (low, intermediate and high) in male ICR mice.
Morphine
given i.c.v. was more potent in inhibiting the tail-flick response evoked by low than high intensity of heat stimulus. beta-Endorphin given i.c.v., on the other hand, was equally potent in inhibiting the tail-flick response evoked by different intensities of heat. This differential effect of morphine and
beta-endorphin
was not shown when morphine and
beta-endorphin
were given i.t.
Morphine
and
beta-endorphin
given i.c.v. or i.t. were equally potent in inhibiting the paw-licking response at different intensities of hot-plate temperature. Our results suggest that morphine given i.c.v. may inhibit high intensity heat-evoked tail-flick response spinally and inhibits low intensity heat-evoked tail-flick response supraspinally. Our results also provide additional evidence for different neural mechanisms of antinociceptive action of morphine and
beta-endorphin
.
...
PMID:Different radiant heat intensities differentiate intracerebroventricular morphine- from beta-endorphin-induced inhibition of the tail-flick response in the mouse. 161 77
Previous studies using a pharmacological approach suggested a neural pathway emanating from the periaqueductal gray (PAG) to the nucleus accumbens relevant to antinociception. This was investigated with neurochemical and histochemical methods in the present study. Push-pull perfusion and radioimmunoassay were used to measure the release of immunoreactive-(ir) enkephalin (ir-ENK) and ir-
beta-endorphin
(ir-beta-EP) in the nucleus accumbens after microinjection of morphine into the PAG and the nucleus raphe dorsalis (NRD) of the rabbit.
Morphine
administration elicited an increase in ir-ENK and ir-beta-EP in the nucleus accumbens. Horseradish peroxidase (HRP) retrograde tracing in combination with 5-hydroxytryptamine (5-HT) immunocytochemistry revealed a serotonergic projection from the NRD and ventral PAG to the nucleus accumbens in the rabbit. About 7% of the serotonin-positive cells in the NRD and ventral PAG send fibers directly to the nucleus accumbens, with an ipsilateral dominance. These results indicate the existence of a serotonergic pathway from the NRD to the N. accumbens involved in opioid analgesia.
...
PMID:Neurochemical and morphological evidence of an antinociceptive neural pathway from nucleus raphe dorsalis to nucleus accumbens in the rabbit. 163 20
Central or systemic administration of morphine disrupts maternal behavior in steroid-primed, pup-induced virgin and lactating rats.
Morphine
, the prototypical mu agonist, also interacts with different opioid receptor subtypes. The present study examined the effectiveness of five receptor-selective agonists, in addition to morphine, to disrupt maternal behavior in primiparous lactating rats following intracerebroventricular (i.c.v.) infusions in order to characterize opioid receptor subtype involvement in maternal behavior in the female rat. Virgin, Sprague-Dawley rats were mated and implanted with lateral ventricle cannulae on days 13-15 of gestation. On postpartum day 5, mothers were tested for maternal behavior 30 min after i.c.v. vehicle infusion (5 microliters). On day 6, rats received one of the following opioid receptor agonists 30 min before testing:
beta-endorphin
(mu/epsilon receptor subtype; 0.29, 0.72, 1.45, 2.9 nmol), DAGO (mu; 0.29, 0.72, 1.45, 2.9 nmol), morphine (mu; 0.29, 0.72, 1.45, 2.9, 14.5 nmol), DPDPE (delta; 2.9, 29 nmol), U50488H (kappa l; 2.9, 29, 145 nmol) and SKF10047 (sigma; 2.9, 29, 145 nmol). Only activation of mu opioid receptors dose-dependently disrupted maternal behavior in primiparous lactating rats. DPDPE, U50488 and SKF10047 had no discernible effect on maternal behavior. DAGO, a highly selective mu agonist, was even more potent than
beta-endorphin
and morphine in disrupting maternal behavior suggesting that maternal behavior is regulated by opioids interacting with the mu opioid receptor.
...
PMID:Opioid receptor subtype involvement in maternal behavior in lactating rats. 165 60
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>